Timothy Rogers1, Veronique Minard-Colin2, Nathalie Cozic3, Meriel Jenney4, Johannes H M Merks5, Soledad Gallego6, Christine Devalck7, Mark N Gaze8, Anna Kelsey9, Odile Oberlin10, Mike Stevens11, Richard D Spicer1, Christophe Bergeron12, Helene Martelli13. 1. Department of Paediatric Surgery, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom. 2. Departement d'Oncologie de l'Enfant et l'Adolescent Institut Gustave Roussy, Villejuif, France. 3. Clinical Research Unit, Agence de la biomedecine Institut Gustave Roussy, Villejuif, France. 4. Department of Pediatric Oncology, Children's Hospital for Wales Heath Park, Cardiff, United Kingdom. 5. Department of Pediatric Oncology Emma Children's Hospital-Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 6. Department of Pediatric Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. 7. Hôpital Universitaire des Enfants Reine Av. J. J. Crocq, Bruxelles, Belgium. 8. Department of Oncology, University College Hospital, London, United Kingdom. 9. Department of Pediatric Histopathology, Royal Manchester Children's Hospital, Manchester, United Kingdom. 10. Departments of Pediatrics, Biostatistics, and Radiation Therapy, Institut, Gustave Roussy, Villejuif, France. 11. TYA South West Cancer Service, Bristol Haematology Oncology Centre, Bristol, United Kingdom. 12. Institut d'hématologie et d'Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France. 13. Chirurgie Pédiatrique Hôpital Bicêtre, Université Paris XI, Orsay, France.
Abstract
PURPOSE: To report the results from International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumors studies (MMT 89 and 95) of males with nonmetastatic paratesticular rhabdomyosarcoma. METHODS: From 1989 to 2003, 159 patients were included. Radical inguinal orchidectomy was recommended, but retroperitoneal lymph node (LN) assessment was based on imaging alone. The treatment was stratified by stage (SIOP tumor-node-metastasis staging system) and histology. RESULTS: Median age at presentation was 5.6 years (range 0.3-17.6) and 120 patients were of <10 years (75%). Patients ≥10 years had tumors of >5 cm more frequently compared to patients of <10 years (54% vs. 22%, P = 0.0004). The 5- year overall and progression-free survivals were 94% and 83%, respectively. Seventy-eight percent of relapses occurred in the retroperitoneal LN. Thirty-one percent of stage N0 patients of age ≥10 years developed node relapse, compared with 8% of N0 patients aged <10 years (P = 0.0005). CONCLUSIONS: Older patients with paratesticular rhabdomyosarcoma have a significant risk of LN relapse. These results support a surgical approach to LN staging in this subgroup of patients.
PURPOSE: To report the results from International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumors studies (MMT 89 and 95) of males with nonmetastatic paratesticular rhabdomyosarcoma. METHODS: From 1989 to 2003, 159 patients were included. Radical inguinal orchidectomy was recommended, but retroperitoneal lymph node (LN) assessment was based on imaging alone. The treatment was stratified by stage (SIOP tumor-node-metastasis staging system) and histology. RESULTS: Median age at presentation was 5.6 years (range 0.3-17.6) and 120 patients were of <10 years (75%). Patients ≥10 years had tumors of >5 cm more frequently compared to patients of <10 years (54% vs. 22%, P = 0.0004). The 5- year overall and progression-free survivals were 94% and 83%, respectively. Seventy-eight percent of relapses occurred in the retroperitoneal LN. Thirty-one percent of stage N0 patients of age ≥10 years developed node relapse, compared with 8% of N0 patients aged <10 years (P = 0.0005). CONCLUSIONS: Older patients with paratesticular rhabdomyosarcoma have a significant risk of LN relapse. These results support a surgical approach to LN staging in this subgroup of patients.
Authors: David O Walterhouse; Donald A Barkauskas; David Hall; Andrea Ferrari; Gian Luca De Salvo; Ewa Koscielniak; Michael C G Stevens; Hélène Martelli; Guido Seitz; David A Rodeberg; Margarett Shnorhavorian; Roshni Dasgupta; John C Breneman; James R Anderson; Christophe Bergeron; Gianni Bisogno; William H Meyer; Douglas S Hawkins; Veronique Minard-Colin Journal: J Clin Oncol Date: 2018-10-23 Impact factor: 44.544
Authors: Timothy N Rogers; Guido Seitz; Jörg Fuchs; Helene Martelli; Roshni Dasgupta; Jonathan C Routh; Douglas S Hawkins; Ewa Koscielniak; Gianni Bisogno; David A Rodeberg Journal: Pediatr Blood Cancer Date: 2021-02-01 Impact factor: 3.838
Authors: Jonathan C Routh; Roshni Dasgupta; Yueh-Yun Chi; Margarett Shnorhavorian; Jing Tian; David O Walterhouse; John Breneman; Suzanne L Wolden; Carola A Arndt; Douglas S Hawkins; David A Rodeberg Journal: Int J Cancer Date: 2020-07-11 Impact factor: 7.396
Authors: Roelof van Ewijk; Reineke A Schoot; Monika Sparber-Sauer; Simone A J Ter Horst; Nina Jehanno; Lise Borgwardt; Bart de Keizer; Johannes H M Merks; Alberto de Luca; Kieran McHugh; Thekla von Kalle; Jürgen F Schäfer; Rick R van Rijn Journal: Pediatr Radiol Date: 2021-06-17